NASDAQ:NRIX Nurix Therapeutics (NRIX) Stock Price, News & Analysis $14.10 -0.14 (-0.98%) Closing price 04:00 PM EasternExtended Trading$14.26 +0.16 (+1.13%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Nurix Therapeutics Stock (NASDAQ:NRIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nurix Therapeutics alerts:Sign Up Key Stats Today's Range$13.65▼$14.4450-Day Range$14.24▼$27.2652-Week Range$12.61▼$28.23Volume2.79 million shsAverage Volume1.75 million shsMarket Capitalization$1.54 billionP/E Ratio6.10Dividend YieldN/APrice Target$34.43Consensus RatingModerate Buy Company Overview Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California. Founded in 2009, it develops medicines that aim to treat cancer and other diseases by changing the levels of specific proteins inside cells. The company’s technology focuses on protein degradation, using the cell’s natural protein-disposal system to remove disease-related proteins. Nurix also researches ways to regulate protein activity through ubiquitin signaling, a process that helps control how proteins function and are broken down. Nurix’s pipeline includes investigational drug candidates, including BTK degraders being studied for B-cell cancers and candidates designed to affect immune-cell signaling. The company has also pursued research and development collaborations with pharmaceutical partners. Its medicines remain under investigation and are not established treatments.AI Generated. May Contain Errors. Read More Nurix Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreNRIX MarketRank™: 3.479770329815 of 5 starsNurix Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 161st out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on no strong buy ratings, 14 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialNurix Therapeutics has a consensus price target of $34.43, representing about 144.2% upside from its current price of $14.10.Amount of Analyst CoverageNurix Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nurix Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nurix Therapeutics are expected to decrease in the coming year, from $1.14 to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nurix Therapeutics is 6.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.88.Price to Earnings Ratio vs. SectorThe P/E ratio of Nurix Therapeutics is 6.10, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.66.Price to Book Value per Share RatioNurix Therapeutics has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nurix Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted18.58% of the float of Nurix Therapeutics has been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 7.17.Change versus previous monthShort interest in Nurix Therapeutics has recently decreased by 8.11%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. News and Social Media1.4 / 5News Sentiment0.28 News SentimentNurix Therapeutics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Nurix Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for NRIX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $893,645.00 in company stock.Percentage Held by Insiders6.70% of the stock of Nurix Therapeutics is held by insiders.Percentage Held by InstitutionsNurix Therapeutics has minimal institutional ownership at this time.Read more about Nurix Therapeutics' insider trading history. Receive NRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRIX Stock News HeadlinesNurix Therapeutics, Inc. (NRIX) Presents at UBS Global Biopharma Conference 2026 TranscriptNovember 17 at 3:21 PM | seekingalpha.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Has Average Price Target of $34.43 According to BrokeragesNovember 17 at 2:33 AM | americanbankingnews.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 18 at 1:00 AM | Behind the Markets (Ad)Nurix Appoints Arati Rao As Chief Medical Officer To Lead Clinical DevelopmentNovember 11, 2026 | rttnews.comNurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical OfficerNovember 11, 2026 | globenewswire.comNurix Therapeutics to Participate in Upcoming Investor ConferencesNovember 10, 2026 | globenewswire.comInsider Selling: Nurix Therapeutics (NASDAQ:NRIX) CFO Sells 4,769 Shares of StockNovember 5, 2026 | insidertrades.comNurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 1,452 Shares of Company StockNovember 3, 2026 | insidertrades.comSee More Headlines NRIX Stock Analysis - Frequently Asked Questions How have NRIX shares performed this year? Nurix Therapeutics' stock was trading at $18.97 on January 1st, 2026. Since then, NRIX stock has decreased by 25.7% and is now trading at $14.10. How were Nurix Therapeutics' earnings last quarter? Nurix Therapeutics, Inc. (NASDAQ:NRIX) posted its earnings results on Tuesday, October, 13th. The company reported $4.73 EPS for the quarter, beating the consensus estimate of ($0.60) by $5.33. The firm had revenue of $673.06 million for the quarter, compared to analysts' expectations of $24.35 million. Nurix Therapeutics had a trailing twelve-month return on equity of 49.34% and a net margin of 42.01%. When did Nurix Therapeutics IPO? Nurix Therapeutics (NRIX) raised $187 million in an initial public offering on Friday, July 24th 2020. The company issued 11,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager. Who are Nurix Therapeutics' major shareholders? Top institutional shareholders of Nurix Therapeutics include State Street Corp (4.05%), Goldman Sachs Group Inc. (1.17%), Pictet Asset Management Holding SA (1.03%) and Soleus Capital Management L.P. (0.82%). Insiders that own company stock include Gwenn Hansen, Houte Hans Van, Christine Ring and Julia P Gregory. View institutional ownership trends. How do I buy shares of Nurix Therapeutics? Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Tesla (TSLA), Vertex Pharmaceuticals (VRTX), NIO (NIO) and Uber Technologies (UBER). Company Calendar Last Earnings10/13/2026Today11/18/2026Jefferies Global Healthcare Conference11/18/2026Fiscal Year End11/30/202638th Annual Healthcare Conference12/02/2026Next Earnings (Estimated)1/27/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, NRIX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NRIX CIK1549595 Webwww.nurixtx.com Phone415-660-5320FaxN/AEmployees357Year Founded2012Price Target and Rating Average Price Target for Nurix Therapeutics$34.43 High Price Target$45.00 Low Price Target$20.00 Potential Upside/Downside+144.2%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)$2.31 Trailing P/E Ratio6.10 Forward P/E RatioN/A P/E GrowthN/ANet Income-$264.46 million Net Margins42.01% Pretax Margin43.91% Return on Equity49.34% Return on Assets38.61% Debt Debt-to-Equity RatioN/A Current Ratio8.44 Quick Ratio8.44 Sales & Book Value Annual Sales$83.98 million Price / Sales18.34 Cash FlowN/A Price / Cash FlowN/A Book Value$5.29 per share Price / Book2.67Miscellaneous Outstanding Shares109,250,000Free Float101,930,000Market Cap$1.54 billion OptionableOptionable Beta1.80 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:NRIX) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.